29 jul. 2019
Cyclomics and its innovative CyclomicsSeq technology were featured in Nature Methods, highlighting the use of Oxford Nanopore sequencing for real-time, bedside cancer diagnostics. The article emphasizes CyclomicsSeq's rapid and cost-effective assay for detecting cancer mutations, showcasing its significant potential in improving patient outcomes.
Cyclomics was prominently featured in a recent Nature Methods article on Nanopore sequencing, underscoring the achievements of the Cyclomics founding team and their innovative technology. This high-impact scientific journal provided a comprehensive historical overview of Oxford Nanopore sequencing advancements, with a particular focus on the MinION instrument's real-time and bedside diagnostic capabilities.
CyclomicsSeq leverages these features, offering a rapid and cost-effective assay for highly accurate cancer mutation detection in blood. By utilizing the Oxford Nanopore MinION, CyclomicsSeq enhances the potential for real-time, point-of-care diagnostics, significantly improving patient outcomes through timely and precise mutation detection.
The inclusion of Cyclomics in such an article highlights the technology's importance and potential impact on the future of cancer diagnostics. The company's collaboration with the University Medical Center Utrecht further strengthens its development, combining clinical expertise with technological innovation to push the boundaries of what is possible in liquid biopsy applications. This recognition not only validates CyclomicsSeq's current capabilities but also sets the stage for future advancements in the field.